Characterization and drug sensitivity profiling of primary malignant mesothelioma cells from pleural effusions

BMC Cancer

Table 4 Correlations of drug efficiency and adjusted drug efficiency with survival

	Drug efficiency vs. survival		Adjusted drug efficiency vs. survival
	R²	p-value	R²	p-value
Pemetrexed	0.36	0.40	0.84	0.09
Chlorambucil	0.14	0.37	0.42	0.08
Hydroxyurea	0.08	0.47	0.32	0.11
Cisplatin	0.46	0.14	0.67	0.05
Doxorubicin	0.05	0.55	0.25	0.17
Paclitaxel	0.24	0.18	0.40	0.07
Asparaginase	0.17	0.27	0.32	0.11
Etoposide	0.00	0.95	0.14	0.32
Docetaxel	0.28	0.14	0.39	0.07
Vinblastine	0.00	0.98	0.08	0.46
Cytarabine	0.08	0.47	0.15	0.30
Vincristine	0.01	0.79	0.07	0.49
Gemcitabine	0.00	0.99	0.05	0.57
Bleomycin	0.37	0.08	0.41	0.06
Cladribine	0.37	0.08	0.38	0.08
Fludarabine	0.01	0.85	0.01	0.81
Oxaliplatin	0.04	0.59	0.04	0.59
Dacarbazine	0.33	0.42	0.33	0.42
Fluorouracil	0.04	0.58	0.04	0.60
Carboplatin	0.05	0.56	0.03	0.63
Topotecan	0.56	0.02	0.54	0.03
Bortezomib	0.05	0.55	0.03	0.64
Vinorelbine	0.03	0.67	0.00	0.96
Methotrexate	0.60	0.01	0.57	0.02
Actinomycin D	0.20	0.23	0.14	0.32
Daunorubicin	0.13	0.34	0.07	0.48
Mercaptopurine	0.11	0.47	0.05	0.63
Prednisolone	0.48	0.04	0.42	0.06
Epirubicin	0.36	0.09	0.22	0.20
Mitomycin C	0.29	0.13	0.05	0.57

For each individual drug a linear regression analysis was performed comparing survival time and drug efficiency or adjusted drug efficiency. The explanatory value (R²) and p-values are sorted according to the largest gain in explanatory value when adjusting the drug efficiency. Statistically significant departure of the slope from 0 was accepted at p < 0.05 and were found for prednisolone and drug efficiency as well as for topotecan and methotrexate, both for drug efficiency and when adjusting the drug efficiency.

ISSN: 1471-2407